Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)

SHE:002550 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	637.46	576.23	409.26	617.81	516.11	202.99
Short-Term Investments	-	64.95	-	-	-	-
Trading Asset Securities	71.06	71.98	67.48	68.23	234.28	662.98
Cash & Short-Term Investments	708.52	713.16	476.73	686.03	750.39	865.97
Cash Growth	40.92%	49.59%	-30.51%	-8.58%	-13.35%	-50.36%
Accounts Receivable	296	275.52	632.87	447.67	461.88	486.58
Other Receivables	4.79	16.9	2.48	2.56	4.81	464.72
Receivables	300.79	292.42	635.35	450.23	466.69	951.3
Inventory	390.77	602.01	536.48	400.63	315.97	245.86
Prepaid Expenses	-	-	-	0.01	0.01	0.01
Other Current Assets	139.6	18.39	38.72	33.04	23.96	26.17
Total Current Assets	1,540	1,626	1,687	1,570	1,557	2,089
Property, Plant & Equipment	524.47	561.27	616.39	611.77	599.56	617.2
Long-Term Investments	290.55	203.22	156.78	40.56	6.71	7.54
Goodwill	11.14	11.14	11.14	11.14	11.14	11.14
Other Intangible Assets	110.26	113.14	100.86	106.92	114.42	119.28
Long-Term Deferred Tax Assets	79.37	90.53	101.49	99.42	105.52	36.38
Long-Term Deferred Charges	122.14	93.77	60.33	46.85	38.14	32.48
Other Long-Term Assets	84.67	67.05	71.67	21.81	19.27	20.96
Total Assets	2,762	2,766	2,806	2,508	2,452	2,934
Accounts Payable	50.13	41.18	45.97	71.23	106.25	62.16
Accrued Expenses	28.94	89.7	101.94	99.55	96.63	47.51
Short-Term Debt	20.02	56.31	103.05	93.56	41.85	344.24
Current Income Taxes Payable	21.87	0.64	0.05	-	15.02	15.55
Current Unearned Revenue	2.94	9.71	15.58	19.67	11.86	-
Other Current Liabilities	61.11	8.28	11.63	12.34	19.38	72.53
Total Current Liabilities	185.01	205.81	278.22	296.35	290.98	541.99
Long-Term Unearned Revenue	88.32	81.85	89.35	93.42	94.87	59.08
Long-Term Deferred Tax Liabilities	4.04	4.52	4.96	0.47	0.5	0.59
Total Liabilities	277.37	292.17	372.53	390.24	386.35	601.65
Common Stock	1,280	1,280	1,280	1,280	1,280	1,280
Additional Paid-In Capital	41.65	41.65	36.29	29.38	25.58	42.91
Retained Earnings	1,323	1,163	1,134	960.89	929.79	1,366
Treasury Stock	-170.86	-30.09	-	-145.05	-154.38	-356.81
Comprehensive Income & Other	0.5	0.36	-0.06	2.23	-0.88	0
Total Common Equity	2,474	2,455	2,450	2,127	2,080	2,332
Minority Interest	10.99	18.98	-16.95	-9.09	-14.56	0.78
Shareholders' Equity	2,485	2,474	2,433	2,118	2,065	2,333
Total Liabilities & Equity	2,762	2,766	2,806	2,508	2,452	2,934
Total Debt	20.02	56.31	103.05	93.56	41.85	344.24
Net Cash (Debt)	688.5	656.85	373.69	592.48	708.54	521.73
Net Cash Growth	42.62%	75.78%	-36.93%	-16.38%	35.81%	-60.24%
Net Cash Per Share	0.54	0.51	0.29	0.49	0.59	0.42
Filing Date Shares Outstanding	1,249	1,275	1,280	1,280	1,280	1,280
Total Common Shares Outstanding	1,249	1,275	1,280	1,280	1,280	1,280
Working Capital	1,355	1,420	1,409	1,274	1,266	1,547
Book Value Per Share	1.98	1.93	1.91	1.66	1.63	1.82
Tangible Book Value	2,353	2,331	2,338	2,009	1,954	2,201
Tangible Book Value Per Share	1.88	1.83	1.83	1.57	1.53	1.72
Buildings	-	498.75	525.73	524.28	448.65	448.64
Machinery	-	558.3	504.84	461.29	426.63	415.59
Construction In Progress	-	8.19	54.1	39.24	76.54	51.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.